AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines.

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Abstract Text:

Michal Entin-Meer,Ada Rephaeli,Xiaodong Yang,Abraham Nudelman,Ayelet Nudelman,Daphne Adele Haas-Kogan,

Butyroyloxymethyl-4-phenylbutyrate (AN-113) is a novel HDACI that releases potent anti-neoplastic derivatives upon intracellular hydrolysis. The precursor of AN-113, 4-phenylbutyrate has shown promising results in a Phase I study of gliomas, and we hypothesized that AN-113 offers significant advantages over the parent drug. AN-113 demonstrates selective in vitro cytotoxicity against malignant cells while sparing normal astrocytes, effective at doses over 20-fold lower than 4-phenylbutyrate. Combining AN-113 and radiation results in additive therapeutic effects. Enthusiasm is lent to this approach by the ability of AN-113 to efficiently kill glioma cells, its bioavailability and potency when administered orally, its capacity to cross the blood-brain barrier, and its effectiveness in combination with radiation.

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Publishing Authors By Initials

M Entin-Meer,A Rephaeli,X Yang,A Nudelman,A Nudelman,DA Haas-Kogan,

For similar pharmaceutical preparations: prodrugs research abstracts see: pharmaceutical preparations: prodrugs research

PUBMED ID PMID:

MEDLINE DATE:

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cancer letters

VOLUME: 253

Page Numbers: 205-14

Journal Abbreviation: Cancer Lett.

ISSN: 0304-3835

DAY: 7

MONTH: 03

YEAR: 2007

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7600053

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Keywords Mesh Terms:

KEYWORDS: Prodrugs

MESH TERMS: pharmacology

Chemical & Substance for Abstract: AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Information

Substance Name: Histone Deacetylases

Registry Number: EC 3.5.1.-

Grant and Affiliation Information for AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines.

AFFILIATION: Department of Radiation Oncology, Neurological Surgery, and Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.

Country: Ireland

AGENCY: United States NCI

GRANT: P50 CA097257

ACRONYM: CA

MEDLINETA: Cancer Lett

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines Related Publications

• AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines.
• Clinical outcomes of intraoperative radiation therapy for extremity sarcomas.
• In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.
• Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma.
• Nutrient-sensitive, antagonistically pleiotropic genes and their contribution to malignant behavior.